Protein tyrosine phosphatase 1B (PTP1B) has been implicated as an important regulator in several signaling pathways including those initiated by insulin and leptin. Potent and specific PTP1B inhibitors could serve as useful tools in elucidating the physiological functions of PTP1B and may constitute valuable therapeutics in the treatment of several human diseases. We have determined the crystal structure of PTP1B in complex with Compound 2, the most potent and selective PTP1B inhibitor reported to date. The structure at 2.15 Å resolution reveals that Compound 2 simultaneously binds to the active site and a unique proximal noncatalytic site formed by Lys41, Arg47, and Asp48. The structural data are further corroborated by results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with Compound 2 and several of its variants. Although many of the residues important for interactions between PTP1B
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and selective PTP inhibitors would be extremely useful in helping to delineate the physiological roles of PTPs and to validate them as therapeutic targets. Furthermore, these inhibitors could provide the foundation upon which therapeutically useful agents can be devised. Unfortunately, as a consequence of the conserved nature of the PTP active sites (i.e., pTyr binding sites), there are currently few PTP inhibitors that exhibit the potency and specificity required for biological and pharmacological investigation.
Fortunately, PTP substrate specificity studies have shown that pTyr alone is not sufficient for high-affinity binding and that residues flanking pTyr furnish additional interactions for specific and high-affinity substrate recognition (14) (15) (16) (17) (18) (19) (20) . These studies, together with the discovery of a second aryl phosphate-binding site adjacent to the active site in PTP1B (21) , demonstrated the potential for multiple site recognition of substrates by PTPs. They also suggested a novel paradigm for the design of potent and specific PTP inhibitors; namely bidentate ligands that bind to both the active site and a unique adjacent peripheral site. Using this approach we have acquired a highly potent and selective PTP1B inhibitor ( Figure 1 , Compound 1), which displays a K i value of 2.4 nM for PTP1B and exhibits several orders of magnitude selectivity in favor of PTP1B against a panel of PTPs (22) . Compound 1 is the most potent and selective PTP1B inhibitor reported to date. This result serves as a proof-of-concept in PTP inhibitor development, as it demonstrates the feasibility of acquiring potent, yet highly selective, PTP inhibitory agents. In order to gain insight into the structural basis of Compound 1's potency and selectivity for PTP1B, and to lay the groundwork for the future design of more potent and specific inhibitors that can interfere with the processes controlled by PTP1B and other PTPs, we have determined the crystal structure of PTP1B in complex with Compound 2 (Figure 1 ).
Compounds 1 and 2 exhibit identical potency and selectivity profiles. In addition, we used a combination of kinetic studies and site-directed mutagenesis to probe the binding interactions between 1 (and several analogs thereof) and PTP1B.
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MATERIALS AND METHODS
Materials. p-Nitrophenyl phosphate (pNPP) was purchased from Fluka. All mutant forms of PTP1B were generated using the QuickChange kit from Stratagene (23) . The oligonucleotide primers used for mutagenesis were from Sigma. All of the mutations were confirmed by DNA sequencing. The catalytic domain of PTP1B (residues 1-321) and its mutants were expressed in Escherichia coli and purified to homogeneity as previously described (21, 23) . The synthesis of 1 was reported in (22) . The preparation of 3 and 5 was described in (24) and (23), respectively.
Solid-Phase Synthesis of 2 and 4. Compounds 2 and 4 were synthesized on the Rink amide resin using a standard protocol for HBTU/HOBt/NMM activation of carboxylic acids. The coupling reaction was performed in DMF for 1.5 hr using a 3-fold excess of acid relative to resin-bound amine. The following compounds were sequentially coupled to the Rink resin to
β-t-butyl ester, and 4-(phosphonodifluoromethyl) phenylacetic acid. Fmoc removal after each coupling was effected with 20% piperidine in DMF. Final cleavage and side chain deprotection was achieved by treatment with trifluoroacetic acid with 5% 1,2-ethanedithiol and 1% m-cresol at room temperature for 3 h. Removal of the solvent in vacuo gave a crude oil that was triturated with cold ether. The crude mixture thus obtained was centrifuged, the ether was removed by decantation, and the resulting white solid was purified by semipreparative reverse phase HPLC (H 2 O/CH 3 CN in 0.1% TFA). Compound 2 was obtained as a white solid by lyophilization.
1 H-
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The following compounds were sequentially coupled to the Rink resin to furnish 4: 
RESULTS
Crystallization and Crystal Packing. Initial crystallization experiments were performed with 1 ( Figure 1 ). After the stock of 1 was depleted, subsequent crystallization trials were conducted with 2 ( Figure 1 ), a synthetic intermediate used to prepare fluorescently labeled or cell permeable analogs of 1. Compound 2 displays the same potency (K i = 1.8 nM) and selectivity toward PTP1B as 1 (K i = 2.4 nM). This is consistent with our previous observations that attachment of an ethyl thiol group to the C-terminal carboxyamide of pTyr did not affect the affinity of substrates for PTP1B (22) . Soaking native PTP1B crystals with either 1 or 2 significantly changed the diffraction patterns, indicating that both inhibitors could bind PTP1B in the crystalline state; however, these data were difficult to process due to high mosaicity of the crystals. PTP1B could be crystallized as very thin needles in the presence of the inhibitor at a 1:3 ratio in the same crystallization conditions of the native protein (25) . Unique to F 2 Pmp, which is a nonhydrolyzable mimic of pTyr, is the difluoromethylene group that replaces the phenolic oxygen in pTyr. The two fluorine atoms at the benzylic position are known to be important for high-affinity binding to PTP1B. For example, when pTyr in the hexapeptide DADEpYL-NH 2 is replaced with F 2 Pmp, the K i for the resulting peptide (200 nM for PTP1B) is over 1000 times more potent than the same peptide containing phosphonomethyl phenylalanine (Pmp) (30) (31) (32) . The structure of PTP1B•2 provides direct evidence for the proposed specific interactions between the fluorine atoms and PTP1B active site residues (31).
As shown in Figure 4C , the fluorine atoms and one of the terminal oxygens of the phosphonate are hydrogen-bonded to an enzyme-bound water molecule that is coordinated by the main-chain nitrogen of Phe182 and the amide side chain of Gln266. A similar water molecule is also observed in several PTP1B-pTyr peptide and PTP1B-difluorophosphonate complexes (20, 33- interactions (17 total, 8 of which are in the range of 3.5-4.0 Å, the remainders are within 4.5 Å)
with the side chains of Phe182, Asp181, and Gln262.
Interactions between 2 and PTP1B beyond the Active Site. In addition to the interactions between F 2 Pmp and the active site, there are extensive and specific interactions between several PTP1B surface residues beyond the active site with the remainder of 2. Figure 4A shows specific polar interactions between 2 and PTP1B. Most notably, Asp48 forms two hydrogen bonds to the main-chain nitrogen and the C-terminal amide of F 2 Pmp. In addition, Arg47 plays a critical role for high-affinity binding of 2. The side chain of Arg47 is highly flexible and can adopt different conformations depending on the nature of the residues immediately N-terminal to pTyr (20) . In the structure of PTP1B•2, Arg47 is found in a conformation that is distinct from those observed in previous studies, enabling Arg47 to make contacts with both the Asp linker and the distal aryl Table 2 . The selectivity profile of 4 for PTP1B against a panel of protein phosphatases is shown in Table 3 .
DISCUSSION
Several years ago we identified a second aryl phosphate-binding site in PTP1B and
proposed that this region of the protein could be targeted for the design of potent and selective PTP1B inhibitors (21 nM. This affinity is nearly 30-fold lower than those of 1 and 2, which may explain the lack of strong interactions between the central F 2 Pmp and PTP1B in the structure of PTP1B/BenzoylGlu-F 2 Pmp-F 2 Pmp-NH 2 . Consistent with the higher affinity of 1 and 2 for PTP1B, the electron density corresponding to 2 and its contact residues in PTP1B are well defined in the structure of PTP1B•2 and highlight extensive interactions involving both the Asp linker and the distal aryl difluorophosphonate, in addition to those observed between the active site and the F 2 Pmp group. oxygen. In addition, the fluorine atoms are also involved in van der Waals interactions with the side chains of Phe182, Asp181, and Gln262 ( Figure 4C ). All of these interactions contribute to the high affinity of 1 for PTP1B, and the interactions with the two fluorine atoms in particular may explain why F 2 Pmp is superior to pTyr or Pmp for binding to the PTP active site. However, these residues that interact with F 2 Pmp are unlikely major contributors to the extraordinary selectivity exhibited by 1 because they are highly conserved among PTPs. Phe182 may be an exception as both His and Gln residues can be found at this position.
Determinants for Potent and Specific
Other residues adjacent to the active site, including Lys41, Arg47, and Asp48, are important for both potency and selectivity of 1 and 2. The carboxylate of Asp48 makes two hydrogen bonds to the amide nitrogens on both sides of F 2 Pmp in 2. In addition, the aliphatic portion of Asp48 is also within van der Waals contacts of the Cα of F 2 Pmp and Cα, Cβ, and Cγ of the Asp linker in 2. Substitution of Asp48 by an Ala reduced the affinity of PTP1B for 1 by 40-fold, which is consistent with the removal of two hydrogen bonds (Table 2) . Because these interactions do not exist between simple bis-aryldifluorophosphonates and PTP1B (34), removal of the side chain of Asp48 does not change the binding affinity for 3 (Table 2) . Interestingly, the affinity of 1 for D48N is enhanced by more than 6-fold, which may result from a reduction of electrostatic repulsion between PTP1B and 1. This supports the notion that residue 48 could be exploited as a determinant of both affinity and selectivity (41) . However, residue 48 is not the sole determinant for 1's affinity and selectivity for PTP1B, since other Asn48-containing PTPs (e.g., SHP1, SHP2, LAR, and PTPα) display more than three orders of magnitude lower affinities toward 1 than does PTP1B (22) . (Table 2) . Moreover, changing the CF 2 in the distal difluorophosphonate in 1 to an oxygen in 5 results in an 11-fold loss of inhibitory activity (23) .
Minor modifications (e.g., addition or deletion of a single methylene group from phosphorylated phenylacetic acid) of the distal element also result in significant decrease in affinity (22) .
Collectively, these results suggest that the interactions of the distal difluorophosphonate with Lys41 are very specific. As controls, removal of side chains from adjacent residues, Leu37, Table 2 ). These results suggest that Arg47 is probably the most important determinant for PTP1B potency and selectivity.
Compound 1 binds to the Y46A mutant 3,400-fold less strongly than the wild-type enzyme. This may be due to compounded effects on both ablation of the π-π interaction between the side chain of Tyr46 and the phenyl ring of F 2 Pmp and disruption of interactions of Arg47 and Asp48 with the rest of 1. Indeed, the π-π interaction between the side chain of Tyr46 and the phenyl ring of the aryl difluorophosphonate only contributes 20-fold to the overall binding affinity between PTP1B and 3 ( Table 2 ).
Much smaller effects (< 4-fold) on the binding of 3 are observed for the Arg47 mutants (Table 2 ). This is consistent with the weak interactions between the guanidinium group and the distal phosphonate (34) . Interestingly, when Arg24, a residue situated in the second aryl phosphate-binding pocket of PTP1B, is changed to an Ala, a more than 3-fold reduction in the affinity of 3 for PTP1B is observed, even though it does not have any effect on the PTP1B-catalyzed pNPP hydrolysis and vanadate binding ( Table 2 ). In contrast, no change in binding affinity of 2 is observed for R24A, in accordance with the finding that the 4-phosphonodifluoromethyl phenylacetic acid moiety in 2 does not interact with Arg24. Together with the lack of discrete electron density outside the active site of the PTP1B•3 structure (unpublished observation), the results raise the possibility that the second difluorophosphonate moiety in 3 may be capable of binding in more than one orientation and may be loosely associated with positively charged residues (e.g., Arg24 and Arg47) on the surface of the enzyme.
The Flexibility of Arg47. PTP1B is somewhat promiscuous in its substrate preference as it dephosphorylates a wide variety of protein/peptide substrates with almost equal efficiency (42).
The structural basis for the plasticity in PTP1B substrate recognition appears to be largely conferred by a single residue, Arg47, which can accommodate both acidic and hydrophobic residues (20) . As depicted in Figure 5 and summarized in Table 4 bears some resemblance to that observed in the PTP1B/EGFR peptide complex with a major difference (52 degree) in the χ 4 value ( Figure 5 and Table 4 ). This rotamer permits optimal interactions between Arg47 with both the Asp linker and the distal aryl difluorophosphonate group. Interestingly, when the Asp linker in 1 is replaced by a Tyr, the affinity of the resulting 4
for PTP1B is only 2-fold less potent than that of 1 (Table 2) . Moreover, Compound 4 is also highly selective for PTP1B, exhibiting 4-fold selectivity over TCPTP and displaying a greater than three orders of magnitude preference for PTP1B versus nearly all phosphatases examined (Table 3 ). In the absence of a crystal structure for PTP1B•4, we manually docked 4 to the structure of PTP1B in the consensus peptide complex. The model suggests that the interactions between Arg47 and 4 are mostly hydrophobic in nature involving the phenyl rings of both the Tyr linker and 4-phosphonodifluoromethyl phenylacetyl group ( Figure 5D ). The model also predicts a polar interaction between a fluorine atom of the distal difluorophosphonate group and the amino group of Lys41, which is supported by the 2-and 4-fold decrease in the binding affinity of 4 for K41R and K41A, respectively ( Table 2 ). The more moderate effects on binding of 4 (as compared to 1) observed for the Arg47 mutants (Table 2) suggest that most substitutions at Arg47 can retain some of the hydrophobic interactions. The results once again highlight the plasticity of Arg47 in PTP1B ligand binding.
Conclusions and Implications for PTP Inhibitor Design.
We have determined the crystal structure of PTP1B in complex with the most potent and selective PTP1B inhibitor identified to date. This structure, together with results from kinetic analyses of the interactions of PTP1B and its site-directed mutants with the inhibitor and several of its variants, provides a molecular explanation for the extraordinary potency and selectivity of 1. The results show that while the nonhydrolyzable pTyr mimic F 2 Pmp occupies the active site, the rest of the molecule interacts with a distinct area involving residues Lys41, Arg47, and Asp48. Thus, in addition to the second aryl phosphate-binding pocket, we have identified another area, positioned within the vicinity of the active site, which can also be targeted to enhance potency and selectivity for PTP1B.
Furthermore, we predict that inhibitors with even higher potency and selectivity can be devised by simultaneously addressing both the new area (defined by Lys41, Arg47, and Asp48) and the second aryl phosphate-binding pocket ( Figure 3B ). Finally, the flexibility of Arg47 should be exploited to incorporate hydrophobic elements in the design strategy in order to improve the physical properties of PTP1B inhibitors (e.g., cell permeability). In principle, an identical approach used for PTP1B (i.e. to develop inhibitors that target both the active site as well as unique adjacent peripheral sites) could also be employed to produce specific small molecule inhibitors for all members of the PTP family that would enable the pharmacological modulation of selected signaling pathways for treatment of various diseases.
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